Danaher in lead in bidding to acquire Abcam, Reuters reports

Danaher (DHR) is in the lead in the fight to acquire Abcam (ABCM) as the biomedical equipment vendor, which has a market value of $5.1B, is said to believe that Danaher’s all-cash offer is superior to a rival bid from Agilent Technologies (A), sources told Reuters’ David Carnevali. The exact price of Danaher’s offer could not be learned, though one source told Reuters that the deal price would be close to Abcam’s current valuation. Abcam shares are up 7.2% in New York.